Navigation Links
BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/6/2008

Presentation will be Web cast live

LAVAL, QC, Nov. 6 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) announces today that on Tuesday, November 11, Mr. Gary Schmid, President and Chief Executive Officer of OVOS Natural Health Inc., a wholly owned subsidiary of BELLUS Health, will present a review of ongoing pharmaceutical and nutraceutical activities at the Rodman and Renshaw 10th Annual Healthcare Conference to be held at the New York Palace Hotel in New York, NY. The presentation will take place at 4:55 P.M. ET.

The live Web cast of BELLUS Health's presentation (audio and visual) can be accessed at http://www.wsw.com/webcast/rrshq14/blus. A replay of the presentation will begin three (3) hours after the actual presentation time, and will be available until November 18, 2008. Please access the Web cast approximately 15 minutes before the presentation is scheduled to begin.

About BELLUS Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs.

To contact BELLUS Health

For additional information on BELLUS Health and its drug development programs, please call the Canada and United States toll-free number 1 877 680 4500 or visit the Web Site at http://www.bellushealth.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s (formerly known as Neurochem Inc.) control. Such risks include but are not limited to: the impact of general econo
'/>"/>

SOURCE BELLUS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
4. BELLUS Health announces closing of Innodia acquisition
5. BELLUS Health provides update on activities
6. Penn study finds pro-death proteins required to regulate healthy immune function
7. UCLA researchers identify markers that may predict diabetes in still-healthy people
8. Air pollution linked to cardiovascular risk indices in healthy young adults
9. More proof needed of safety and quality of electronic personal health records
10. Health care incentive model offers collaborative approach
11. Loneliness is bad for your health

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...TRIANGLE PARK, N.C., Dec. 1 Max Ne...have expanded over the years serving the top most ...ich was originally set up in an area of 2000 sq. f...part of the suite of services by Max Neeman, are r...ble offering. ,, The pharmacy inventory managem...
(Date:12/1/2009)... Dec. 1 Individuals in ...ly than those with traditional coverage to exhibit...engaged in wellness programs, and to be more incli...olding down costs, according to survey results rel...search Institute (EBRI). ,, At the same time, ...
(Date:12/1/2009)...RDALE, Fla., Dec. 1 OrbusNeich tod...in the randomized clinical trial of the Combo Bio-...,, A prospective, randomized, multicenter study...u M inal sirolimus coat ED bio- E ngineered...ites in Asia, Australia, Europe and South America ...
(Date:12/1/2009)...California are unable to successfully obtain infor... despite recent state legislation intended to impr..., Posing as low-income uninsured patients, resea...-third of the hospitals they approached and the es... allowed under California law, according to the fi...
(Date:12/1/2009)... Lumension announces general availability of its ...ver end-to-end endpoint management capabilities on...nt console architecture. , ...sion, a global leader in endpoint management and s...dpoint Management and Security Suite (LEMSS) tha...
Breaking Medicine News(10 mins):Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 2Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 4Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:Hospital price transparancy laws in California fall short, study finds 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 3Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 4Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 5Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 6
...lease is available in French . , A collaborati...ogical Institute (MNI), McGill University has demo... and cortical thickness in the brains of healthy 6... week in a special issue of scientific journal In...
...Texas, March 25 ULURU Inc. (NYSE Alternext: ULU) ...ce call to discuss the fourth quarter and year end...siness update on Tuesday, March 31, 2009 at 10:00 ...304#) five to ten minutes prior to the initiation ...
...e Call Today to Follow Release , , DENVER, March ... or the "Company") (OTC Bulletin Board: GLOB), an ...logy company, will report its fourth quarter and y...p://www.newscom.com/cgi-bin/prnh/20040226/GLOBALME...
...tive growths 3 times more likely regardless of age...h 25 (HealthDay News) -- Black women are three tim...p aggressive breast cancer, a U.S. study finds. , ...k women do get breast cancer, it,s often more adva...
...y 20 March, US researcher Dr. Chris Beecher from t...ture about sarcosine, an N-methyl derivative of th...ess in Stockholm, Sweden. Dr Beecher is a colleagu... with prostate cancer. These findings suggest that...
... March 25 An amazing medical discovery that provi... (ED) is in the US and looking to make the big th... News Release, go to: http://www.prnewswire.com/m...te Hydropump reverses Erectile Dysfunction throu...
Other Medicine News:Health News:When it comes to intelligence, size matters 2Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update 2Health News:Global Med Technologies(R), Inc. to Report Fourth Quarter and Year End Financial Results Today 2Health News:Black Women at Higher Risk for Aggressive Breast Tumors 2Health News:A new approach to prostate cancer detection 2Health News:Video: Bathmate Hydropump Poised to Replace Cialis, Levitra, and Viagra 2
(Date:12/1/2009)..., , ALBUQUERQUE, N.M., Dec. 1 /PRNewswire/ -...s laboratory that discovers, develops and markets ...ointment of Scott Glenn as chairman of the company... ,, Prior to joining Exagen, Glenn was managing... of a number of successful biomedical companies in...
(Date:12/1/2009)..., , CHENGDU, China, Dec. 1 /PRNews..., Inc., (NYSE Amex: TPI ), a manufacturer and sup..."TCM") based in Chengdu, China, today,announced th...e Food and Drug,Administration (SFDA) to produce P...m of 10 ml/tube (SFDA approval number Z20093060) a...
(Date:12/1/2009)..., , BEIJING, Dec. 1 /PRNewswire-A...ding provider of biopharmaceutical products in Chi...h purchase order for its H1N1 vaccine, PANFLU.1(TM...on Technology for the national,purchase plan. Unde...uce an,additional one million doses of PANFLU.1 (T...
Breaking Medicine Technology:Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 3Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 3Selective Insurance Group Announces Officer Appointments 56161 1Selective Insurance Group Announces Officer Appointments 56161 2Selective Insurance Group Announces Officer Appointments 56161 3XLHealth Appoints New Controller to Lead Financial Compliance Accounting Initiatives 56160 1XLHealth Appoints New Controller to Lead Financial Compliance Accounting Initiatives 56160 2Kroger Selects WaveSense Diabetes Testing Products 56156 1Kroger Selects WaveSense Diabetes Testing Products 56156 2
...N DIEGO, July 28 Cadence Pharmaceuticals,Inc. (Na... on in-licensing,developing and commercializing pr...n the hospital setting, today announced that it wi...fore the market opens on Thursday,August 7, 2008.,...nd live webcast to,discuss the financial results a...
...Two Large-Scale Analyses Have Conflicting Results ...in memory and thinking processes among placebo gro...educe the ability to show the effectiveness,of new...ported today at the,2008 Alzheimer,s Association I...AD 2008) in Chicago., Alzheimer clinical trials s...
Other Medicine Technology:Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008 2Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 2Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 3Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 4Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials 5
...channel within a 12.1mm insertion tube. It featur...d image for improved reliability, an electronic be...5 and 5.0mhz transducer for deeper ultrasound imag...ical orientation and vascular evaluation during re...
...of diagnosis by using the Convex Scanning method. ...od flow by using the Color Flow Mapping and Color ...rated and the balloon fixation has improved. Those...curate techniques. The FG-36UX expands the possibi...
ACL 1000 Coagulation Analyzer
SYNCHRON CX®5 Delta
Medicine Products: